Detalles de la búsqueda
1.
The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients.
Blood
; 143(11): 983-995, 2024 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37979133
2.
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA.
Blood
; 137(17): 2307-2320, 2021 04 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-33211799
3.
Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Eur J Nucl Med Mol Imaging
; 48(5): 1362-1370, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33097974
4.
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
Blood
; 131(22): 2449-2453, 2018 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-29559480
5.
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.
Lancet Oncol
; 20(2): 202-215, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30658935
6.
Role of positron emission tomography for the monitoring of response to therapy in breast cancer.
Oncologist
; 20(2): 94-104, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25561512
7.
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project.
Haematologica
; 105(1): e33-e36, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31371411
8.
PET-guided, BEACOPPescalated therapy in advanced Hodgkin lymphoma - Authors' reply.
Lancet Oncol
; 20(4): e190, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30942177
9.
Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Lancet Oncol
; 15(13): 1493-1502, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25456368
10.
¹8F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Eur J Nucl Med Mol Imaging
; 41(3): 428-37, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24196916
11.
Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.
Eur J Nucl Med Mol Imaging
; 41(9): 1735-43, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24811577
12.
HER2-positive breast cancer: ¹8F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
Eur J Nucl Med Mol Imaging
; 41(8): 1525-33, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24647576
13.
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.
Eur J Nucl Med Mol Imaging
; 41(3): 416-27, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24258007
14.
Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma.
Eur J Nucl Med Mol Imaging
; 41(11): 2017-22, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24902639
15.
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
Blood
; 118(1): 37-43, 2011 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-21518924
16.
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
Eur J Nucl Med Mol Imaging
; 40(9): 1312-20, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23649463
17.
Validation of the ΔSUVmax for Interim PET Interpretation in Diffuse Large B-Cell Lymphoma on the Basis of the GAINED Clinical Trial.
J Nucl Med
; 64(11): 1706-1711, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37734837
18.
High PDL1/PDL2 gene expression correlates with worse outcome in primary mediastinal large B-cell lymphoma.
Blood Adv
; 7(23): 7331-7345, 2023 12 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37862676
19.
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study.
Leuk Lymphoma
; 63(13): 3063-3071, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35975738
20.
Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.
J Clin Oncol
; 40(10): 1091-1101, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34990281